This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Beyonttra Banner.

Beyonttra
®
▼(acoramidis)

All-cause mortality in the open-label extension

Beyonttra - Patient Image

Continuous Beyonttra® significantly prevented death compared to the placebo-to-Beyonttra arm at Month 42

  • Participants who completed the 30-month ATTRibute-CM study were invited to participate in the OLE study.
  • Participants who previously received acoramidis continued to receive it (continuous acoramidis), and those who received placebo through month 30 were switched to acoramidis (placebo to acoramidis).
  • All participants received BEYONTTRA® 800 mg BID.

All-cause mortality in the ATTRibute-CM study:

All-cause mortality in the ATTRibute-CM study_Graph
All-cause mortality in the ATTRibute-CM study_Graph

Abbreviations:
 

ACM
, all-cause mortality;
ARR
, absolute risk reduction;
ATTR-CM,
 transthyretin amyloid cardiomyopathy;
CI
, confidence interval;
HR,
hazard ratio.

 

PP-BEY-IE-0037-2   |   June 2026

 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.

    • 1
      Judge DP, et al. Circulation. 2025;151(9):601 – 611
    • 2
      Poulsen SH, et al. Presented at: International Symposium on Amyloidosis 2024; May 26–30, 2024; Rochester, MN. Poster #2024-ISA-B-279